Cheddar. Dough. Loot. Make more Moolah here.
BONUS & INCENTIVES
SCROLL DOWN TO SEARCH BY CATEGORIES
|
Dear Agents, We have an important update regarding the Health Risk Assessment (HRA) Incentive Program, along with some highlights for our 2024 plans! Changes to HRA Incentive Program Eligibility: Effective today, the My Choice CalPlus (HMO) 007 (FULL DUAL or LIS) plan is no longer eligible for the HRA incentive program. However, any HRAs submitted for this plan before today will still be honored, and you will receive the corresponding incentive in the month of the Member’s effective date. While the My Choice CalPlus (HMO) 007 HRA incentive is no longer available, please continue your efforts with our other eligible plans. You will still earn $150 for each HRA conducted for D-SNPs and $100 for C-SNPs, as outlined below. 2024 Plan Highlights - Heart & Diabetes CalPlus (C-SNP) 039: We want to highlight the Heart & Diabetes CalPlus (C-SNP) 039, a Chronic Special Needs Plan specifically designed for full-dual chronic members. The benefits significantly improve upon the My Choice CalPlus 007 plan, providing enhanced coverage and support for our members. In addition, the Heart & Diabetes CalPlus (C-SNP) 039 plan also offers an HRA incentive of $100. We encourage you to explore the opportunities this plan presents, especially for your current My Choice CalPlus 007 chronic dual members, and continue making a positive impact on the well-being of our members. Improved Functionality: To streamline your HRA submission process, we've built the functionality directly into the broker portal. Simply log in, click on the "My Clients" tab, and find the client needing an HRA. Broker portal will now inform you whether the member is eligible for an HRA or not. This enhancement aims to make the process more efficient and user-friendly. You'll earn $150 by completed an HRA for any of the 2024 plans below: ARIZONA
the ONE / el ÚNICO (HMO) 001 (FULL DUAL or LIS) You'll earn $100 by completed an HRA for any of the 2024 plans below:
ARIZONA
0 Comments
|